PATENT APPLICATION (13/0)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	Applicants: Batra et al.	)	Exammer.	
	••	· )	Not Yet Assigned	
	Serial No.: Not Yet Assigned	)		
	(Continuation application of	)	Previous Examiner	
	USSN 09/312,617)	)	Sharareh, S.	14. 511
		)		A SE SE
	Docket No.: 20243CA	)	Art Unit: Not yet a	ssigned 2 Law .
		)	•	A SEE SE
	Express Mailed: June 29, 2001	)	Previous Art Unit:	467 # 25 8 5 4 3 1 1
	,	)	를 <i>(</i>	人名音音音音
	For: "COMPRESSED TABLET FORMULATION"	)	C. C	A 4 5 2 4 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
		·	AL.	12 EE 2 2 5 8 7 2
	Box PATENT APPLICATION		₩	THE RESERVE
			J. J	
	Assistant Commissioner for Patents		ă	F 6 E 8 8 B F 7
	Washington, D.C. 20231			S H S G S S S S S S S S S S S S S S S S
				THE STATE OF THE S
PRELIMINARY AMENDMENT				
	I KEENVIII VIIKT PRIVES	10111111		

Sir:

Applicants request entry of this amendment prior to examination of the above-identified application, which is a Rule 53(b) continuation of USSN 09/312,617. Please amend the above-identified application as follows:

## IN THE SPECIFICATION:

Please insert the following paragraph on page 1 after the Title:

-- This application is a continuation of US Serial No. 09/312,617, filed January 17, 2001, which is a continued prosecution application under 37 C.F.R. § 1.53(d) of US Serial No. 09/312,617, filed May 17, 1999, now abandoned, which claims the benefit of US Provisional Application No. 60/086,921, filed May 27, 1998.--

Replace the fourth paragraph on page 7 with the following paragraph:

-- The formulation also is bioequivalent to a capsule with a smaller dose (200 mg), and more bioavailable than other tablet compositions. The advantages over the capsule include robust processing and sorting steps, smaller size with a larger dose, and market preference. The